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Abstract
Background: Disruption of the frontal lobes and its associated networks are a common consequence of
neurodegenerative disorders. Given the wide range of cognitive, behavioral and motor processes in which the
frontal lobes are involved, there can be a great variety of manifestations depending on the pathology distribution. The
most common are the behavioral variant of frontotemporal dementia (bvFTD) and the frontal variant of Alzheimer’s
disease (fvAD), which are particularly challenging to disentangle. Recognizing fvAD from bvFTD-related pathologies is a
diagnostic challenge and a critical need in the management and counseling of these patients.
Case presentation: Here we present three pathology-proven cases of Alzheimer’s disease initially misdiagnosed as
bvFTD and discuss the distinctive or less overlapping historical, examination, and laboratory findings of fvAD
and bvFTD, deriving analogies for mnemonic endurance from the Wizard of Oz worldview.
Conclusion: The Yellow Brick Road to diagnosing these disorders may be served by the metaphor of fvAD as
the irritable, paranoid, and tremulous Scarecrow and bvFTD the heartless, ritualistic, and rigid Tin Man. An Oz-inspired
creative license may help the clinician recognize the differential disease progression, caregiver burden, and treatment
response of fvAD compared with bvFTD.
Keywords: Frontal variant of Alzheimer’s disease, Frontotemporal Dementia, Movement disorders, Parkinsonism,
Behavioral disorder
Introduction
While an amnestic syndrome is the most common pres-
entation of Alzheimer’s disease (AD), atypical variants
have been recognized. These include the posterior cor-
tical atrophy syndrome, corticobasal syndrome, logope-
nic variant of primary progressive aphasia, and frontal
variant (fvAD) [1, 2]. FvAD is an under-recognized form
of AD, often misdiagnosed as more common frontal lobe
syndromes such as the behavioral variant of frontotem-
poral dementia (bvFTD) or vascular dementia affecting
frontal networks. We present three patients with
pathology-proven AD presenting with cognitive and be-
havioral impairment in the context of parkinsonian fea-
tures, initially diagnosed as bvFTD. We then discuss the
features in the history, examination and ancillary testing
that may have helped distinguishing these entities. Fi-
nally, we suggest analogies from Frank Baum’s novel
“The Wonderful Wizard of Oz” to help the reader
(without trivializing) remember the phenotypic differ-
ences between them.
CASE #1
A 72-year-old man had progressive decline in gait and
cognition following a fall 10 months earlier. He was for-
getful and his gait shuffling and unstable. In the follow-
ing months, his family noted a change in personality
with apathy and lack of concern for his appearance. His
family history was significant for AD in his mother and
Parkinson disease (PD) in two paternal cousins. On
exam, he was hypophonic and hypomimic. He exhibited
symmetric rigidity and bradykinesia and hand myoclonus
on outstretched arms. His gait was slow and short-
stepped, with stooped posture, reduced arm swing, gait
freezing on turns, and inability to tandem walk
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(Additional file 1: Video S1). Postural reflexes were im-
paired. Unified Parkinson’s Disease Rating Scale (UPDRS)
motor score was 23.5 on initial examination. In addition,
he demonstrated bilateral ideomotor apraxia to transitive
gestures. Montreal cognitive assessment (MoCA) score
was 21/30 with deficits in executive function, phonemic
fluency, and attention. Frontal assessment battery (FAB)
was 15/18. His brain MRI revealed atrophy in the frontal,
temporal, and parietal regions, somewhat worse in the
right hemisphere, with increased signal in the periven-
tricular white matter and right frontal lobe (Fig. 1a, d).
Patient and family declined amyloid-imaging and cere-
bral spine fluid (CSF) biomarkers. A diagnosis of pos-
sible bvFTD with parkinsonism was made based on
apathy, poor personal hygiene, and predominantly ex-
ecutive dysfunction on cognitive testing. Levodopa was
titrated to a dose of 1600 mg/day with mild improve-
ment in gait speed but also with development of mild
truncal dyskinesia. Clonazepam 0.5 mg daily and venla-
faxine 75 mg daily were sequentially added with mild
benefit on sleep and depressive symptoms, respectively.
His cognition continued to deteriorate despite a trial of
rivastigmine. Unfortunately, he later suffered multiple
strokes, severely affecting his cognition and ambulation,
rendering him wheelchair bound. His condition deteri-
orated further and he died 7 years after the onset of his
symptoms.
Brain autopsy showed mild symmetric cerebral atro-
phy in the frontal and temporal lobes with multiple
grossly evident infarcts. The brain weighed 1260 grams.
Microscopic evaluation demonstrated moderate to se-
vere neurofibrillary tangles in mesial temporal structures
and association areas of the neocortex, Braak stage V
and amyloid, Braak, CERAD (ABC) score of B3, associ-
ated with frequent neuritic plaques throughout the neo-
cortex, most prominently in the middle frontal, superior
and middle temporal gyri, and inferior parietal lobule
resulting in C3 scoring on ABC. Along with extensive
beta amyloid deposition (A3), these findings were con-
sistent with a high degree of AD neuropathology per the
National Institute on Aging-Alzheimer’s Association
(NIA-AA) criteria [3–7]. No tau immunoreactive glial
deposits were identified. There was mild patchy neur-
onal loss, moderate neurofibrillary tangles, and scattered
senile plaques in the substantia nigra with moderate
neuronal cell loss and gliosis in the putamen. There was
coexistent cerebrovascular disease, with moderate ath-
erosclerosis of major arteries and diffuse arteriolosclero-
sis. Remote macroscopic infarcts were noted in the left
occipital lobe, right middle frontal gyrus, right anterior
medial aspect of superior frontal gyrus, and bilateral
cerebellar hemispheres.
CASE #2
This 79-year-old man presented with a 6-year history
of worsening gait and balance. He initially complained
of heaviness in his legs followed by forgetfulness and
a tendency to stumble and fall. He also manifested
word-finding difficulties and impaired visual naviga-
tion. Four years after symptom onset, he developed
paranoid ideation and anxiety during a trial of levodopa to
address presumed PD. Within months, he became more
belligerent, disinhibited, irritable and uncharacteristically
offensive. He frequently cried and endorsed depression.
Fig. 1 Brain MRI of Case #1–3. Sagittal T2-weighted (upper row) and axial FLAIR (lower row) brain MRIs. Patient 1 (a and d) showed mild to moderate
atrophy in the frontotemporal regions, minimally asymmetric, with right frontal encephalomalacia. Patient 2 (b and e) showed similar findings
with somewhat lower burden of associated periventricular and spotty subcortical white matter increased signal. Patient 3 (c and f) showed
mild diffuse atrophy with minimal periventricular and subcortical white matter disease
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Word-finding difficulties were compounded by seman-
tic paraphasias (“garage” instead of “cabinet”). He had
trouble locating food on his plate when eating. His gait
continued to deteriorate with increased freezing and in-
stability, ultimately leaving him wheelchair dependent.
His mother developed dementia of unknown etiology in
her late seventies. On exam, he was alert but his verbal
output truncated with hesitations, semantic and phon-
emic paraphasias, echolalia and palilalia. He was unable to
follow three-step commands. He exhibited hypomimia,
bradykinesia and rigidity, but no tremor (Additional file 2:
Video S2). UPDRS motor score was 32.5 on initial evalu-
ation. He demonstrated frontal-localizing signs, including
grasp reflex and perseverative behaviors. His brain MRI
showed moderate atrophy in the frontal and temporal
lobes, with increased periventricular and deep white mat-
ter signal abnormality (Fig. 1b, e). Mini-mental status
exam score was 28/30 and MoCA 23/30, with deficits in
executive function and delayed recall. Visuospatial orien-
tation as per clock drawing and figure copying was normal
despite complaints of impaired visual navigation possibly
suggesting an attentional deficit. A diagnosis of probable
bvFTD was made based on disinhibition, loss of empathy
(based on pejorative comments), frontal dysfunction, and
MRI findings. The patient died within a year from his only
visit from a myocardial infarction. Amyloid-imaging and
cerebrospinal fluid biomarkers were not performed.
Gross pathology demonstrated symmetric cortical atro-
phy in the frontal, anterior, and mesial temporal lobes.
Gross brain weight was 1150 g. Microscopy revealed a high
degree of AD neuropathologic changes based on NIA-AA
guidelines: widespread beta amyloid deposition (A3), neur-
itic plaques within the neocortex (C3), and neurofibrillary
tangles throughout the mesial temporal structures and
association areas of the neocortex (Braak stage V and
B3) [3–7]. Additionally, alpha-synuclein-positive Lewy
bodies were noted in the brainstem (including substan-
tia nigra) and limbic regions, with coexistent mild glio-
sis in the putamen, suggesting coexistent Lewy body
disease (Limbic type, Braak stage IV) [7, 8]. The limited
distribution of α-synuclein pathology in cerebral struc-
tures suggested that it contributed to the parkinsonian
features but was unlikely to have caused the memory
and behavioral complaints. No tau-immunoreactive
glial deposits or any TDP-43 positive inclusions were
identified.
CASE #3
This 78-year-old woman presented with a 9-month his-
tory of worsening mood and behavioral changes associ-
ated with language difficulties and parkinsonism. Nine
months prior to presentation, family members observed
she was overly emotional, crying and laughing often
without endorsing sadness or happiness. In the following
months, the family noticed an asymmetric rest and
action tremor in her right hand and gait shuffling, requir-
ing a walker for ambulation 6 months before presentation.
Her speech became dysfluent, with echolalia and palilalia.
Forgetfulness worsened and she required assistance in all
activities of daily living. When going to the bathroom to
wash her hands, she would frequently lower her pants and
finish urinating in other rooms. On examination, she had
a monotone speech with hypophonia, symmetric bradyki-
nesia and rigidity, mild right-hand rest tremor, and im-
paired postural reflexes (Additional file 3: Video S3).
UPDRS III motor score was 47 on initial evaluation. Root,
snout, and glabellar reflexes were present. MoCA score
was 8/30 with deficits in all domains, except naming. MRI
showed mild diffuse generalized atrophy (Fig. 1c, f ). Given
her behavioral changes with disinhibition and compulsive
behaviors, the patient was diagnosed with possible bvFTD
associated with parkinsonism. Levodopa was initiated and
titrated up to 500 mg four times daily with moderate
benefit on her motor symptoms. Multiple medications
were tried over the next few years including valproic acid,
lamotrigine, aripiprazole, dextromethorphan/quinidine,
and oxazepam with only modest benefit for emotional la-
bility. Citalopram provided the sustained improvement in
mood. The patient continued to deteriorate and died
10 years after symptom onset.
Autopsy revealed mild to moderate cortical atrophy,
more prominent in the frontal lobes. The brain weighed
1030 grams. The histological hallmarks of Alzheimer
disease, abundant neuritic plaques (C3) and neurofibril-
lary tangles (B3), were identified by beta-amyloid and
tau immunohistochemistry. Extensive diffuse deposits
of beta-amyloid (A3) were also seen in the cerebrum
and cerebellum. By NIA-AA criteria, the findings met
criteria for “high level” AD neuropathology [3–7]. Rare,
scattered tau-positive neurons were identified in the
globus pallidus and putamen but insufficient to be clas-
sified as FTD-Tau. Minimal focal neuronal cell loss and
gliosis is noted in the substantia nigra with occasional
neuromelanin-laden macrophages.
Review
These three cases highlight the extent to which behav-
ioral abnormalities may overshadow cognitive impair-
ment in fvAD, the lesser known focal variant of AD,
leading to the clinical misdiagnosis of bvFTD. Some
studies have suggested that fvAD accounts for approxi-
mately 2–3% of AD, [1, 2], although this figure is likely
higher because AD pathology can be found in up to 25%
of patients with a clinical diagnosis of bvFTD [9, 10].
The appropriate clinical distinction between fvAD and
bvFTD has implications for prognosis, treatment, disease
progression, and caregiver burden [11–15].
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The clinical diagnosis of bvFTD is currently based on
the presence of behavioral changes antedating cognitive
deficits with a sensitivity of 76–95% and specificity of
82–95% [16, 17]. Typically, the presentation is character-
ized by changes in personality and behavior, most notably
apathy, disinhibition, loss of self-awareness, and loss of
empathy [11, 18]. A dysexecutive cognitive impairment
emerges later in the course of the disease with difficulties
in sustaining attention and set shifting. bvFTD is most
often caused by frontotemporal lobar degeneration
(FTLD) proteinopathies, namely tauopathies (of which
microtubule-associated protein tau (MAPT) gene muta-
tions are the most common genetic causes), TDP-43 pro-
teinopathies (of which chromosome 9 open reading frame
72 (C9orf72) and progranulin (GRN) gene mutations, in
order of frequency, are most common), and less fre-
quently, fused in sarcoma (FUS) proteinopathies [19]. In
cases of bvFTD-associated parkinsonism, tau is the most
common underlying proteinopathy [20].
Unlike bvFTD, the phenotype in fvAD is less well de-
lineated, with heterogenous clinical descriptions from
case reports and case series. Nevertheless, an early
amnestic phase, with memory dysfunction preceding
changes in behavior may be more common in fvAD
[21]. Not only is the behavior-cognition sequence
different between fvAD and bvFTD, but the nature of
the impairments may differ as well.
In addition, vascular pathology may confound the
evaluation of frontal lobe syndromes, including fvAD
and bvFTD. Small and large vessel vasculopathy can dis-
rupt frontal lobe networks in a manner suggestive of
(and potentially in addition to) fvAD and bvFTD. The
clinical heterogeneity of the clinical entities and overlap
of comorbitities make ascertaining the correct diagnosis
a humbling experience, as demonstrated by all three of
our cases carrying a diagnosis of bvFTD during life but
reclassified as fvAD on autopsy.
The Yellow brick road
Acknowledging the limitations of classic literature-based
metaphors to provide a memorable analogy to what an
otherwise complex clinical dilemma, we propose consider-
ing the “Yellow Brick Road” from the Wizard of Oz char-
acters to remember the clinical variables to consider when
facing the fvAD vs. bvFTD clinical distinction (Fig. 2).
The Scarecrow, who had no brain, allegorizes fvAD.
Without a brain the fvAD Scarecrow lost the ability to
consolidate new memories and object knowledge
(Fig. 2a). Although fvAD Scarecrow can produce a list of
words based on letters, suggesting an intact phonemic
Fig. 2 fvAD and bvFTD in the Wizard of Oz. a fvAD Scarecrow was searching for a brain because he had none, and without a brain he had no
memory or object knowledge. While his phonemic fluency was preserved, fvAD Scarecrow had difficulty with semantics and was irritable and
paranoid, believing the crows were gearing to bothering and stealing from him. Furthermore, fvAD Scarecrow was very tremulous (myoclonus).
The wind could suddenly jolt him (stimulus-sensitive myoclonus). b bvFTD Tin Man had no heart, so his behavior and emotions were affected
from the outset. The “heartless” bvFTD Tin Man lacked empathy and was very ritualistic, only going out to chop wood. His rituals included
hyperphagia, making him heavier than the straw-filled fvAD Scarecrow. Furthermore, bvFTD Tin Man was insufficiently lubricated, making him appear
parkinsonian. This particular bvFTD Tin Man was missing progranulin, rendering his frontotemporal region asymmetric, as judged by a crooked hat.
Both images are from 1900; US Copyright law on public domain
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fluency, the meanings of words is lost and therefore se-
mantic fluency and semantic knowledge are impaired.
fvAD Scarecrow is irritable and paranoid, believing the
crows are swarming to torment and steal from him. Fur-
thermore, fvAD Scarecrow is shaky and tremulous,
movements that on closer inspection represent myoclo-
nus. The fvAD Scarecrow is also sensitive, the slightest
whisper or touch can startle him, because of stimulus-
sensitive myoclonus.
The Tin Man symbolizes bvFTD (Fig. 2b). bvFTD Tin
Man has no heart, so his behaviors and emotions lack
empathy. He engages in ritualistic and perseverative be-
haviors, repetitively venturing to the forest to chop wood
and gorge. His rituals included hyperphagia, making him
heavier than the fvAD Scarecrow. Furthermore, bvFTD
Tin Man is insufficiently lubricated: the rust at the joints
slow him to a parkinsonian state.
Chronology of symptoms
Determining the chronology of symptoms is of fundamen-
tal importance in the prediction of the underlying
pathology of patients with cognitive and behavioral im-
pairments. Patients with bvFTD tend to present with be-
havioral changes first, which are followed by executive
dysfunction and language disturbances (Fig. 3). Con-
versely, in fvAD memory impairment is the first abnor-
mality in up to 85% of patients (Fig. 4), with the
remainder developing memory impairment within 3 years
from symptom onset [1, 22, 23]. Our cases highlight the
difficulty in determining the sequence of symptoms, and
highlight the heterogeneity of and overlap between the
fvAD and bvFTD phenotypes. While not apparent in our
cases, studies have demonstrated that executive or behav-
ioral dysfunction typically develop after memory deficits
in fvAD [1, 22, 23].
Memory and language dysfunction
Memory impairment may be due to disruptions in any
of the three stages of memory processing: registration,
consolidation, and retrieval. While registration relies
upon the integrity of more diffuse attentional and per-
ceptual networks, consolidation hinges on temporal
(hippocampal based) networks, and memory retrieval on
frontal networks. While bvFTD patients may have mild
difficulty with free recall early in the disease, recognition
memory is typically intact and thus patients are able to
recognize items with cueing, consistent with a retrieval-
predominant deficit [24]. Early recall impairment in
fvAD is due to the inability to consolidate memories
[25]. As memory is not formed, cueing is of no benefit,
which was the case in our patients –a missed clue as to
the underlying pathology.
Language impairment also shows different patterns in
bvFTD and fvAD. In bvFTD, language dysfunction is ini-
tially absent, unlike other frontotemporal dementia phe-
notypes, namely progressive nonfluent aphasia and
Fig. 3 Chronology of symptoms. The diagram illustrates the severity and timing of cognitive impairments, motor manifestations, and behavioral
changes as they may appear across disease stages in bvFTD
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semantic dementia [17]. In our experience, the “social-
emotional” aspects of speech, rather than language it-
self, may be impaired, with inability to understand the
subtleties and context of conversations, hence the ana-
logy to a “heartless” Tin Man. Progressive language de-
terioration may occur late in bvFTD. The fvAD
Scarecrow, “who lacks a brain”, may more often present
with word-finding difficulties, anomia, and semantic
paraphasias. Fluency may also be helpful in differentiat-
ing both disorders. While semantic (category) fluency is
usually impaired to a greater degree in fvAD, phonemic
(letter) fluency is more affected in bvFTD [17]. Interest-
ingly, the use of profanity during verbal fluency testing
has been shown to be more suggestive of bvFTD than
AD [26]. We hypothesize that the use of pejoratives
seen in case #2 was a filler for word-finding difficulty,
with over-utilization of an overlearned phrase, rather
than an indicator of disinhibition. Case #3, in which the
patient had progressive anomia, was more typical of
fvAD in retrospect.
On the other hand, executive dysfunction may not
be helpful in distinguishing between underlying de-
generative processes. Only one study has shown
worse executive function in fvAD compared to
bvFTD but such difference may have been con-
founded by the presence of comorbidities such as
cerebrovascular disease, sleep apnea, medication side
effects, metabolic dysfunction, and inflammatory con-
ditions [21]. The associated cerebrovascular disease in
cases #1 and 2 may have contributed to non-specific
frontal dysfunction.
Personality change and behavioral disturbances
Personality changes are more common in patients with
bvFTD than fvAD, with differences in the nature of the
personality change shedding light on the underlying
diagnosis [10, 22]. Patients with bvFTD are most likely
to exhibit disinhibition, and are often described as so-
cially inappropriate [21]. Moreover, unlike fvAD “Scare-
crows”, bvFTD “Tin Men” may be cold, more apathetic
and less empathetic, creating tension with caregivers.
We hypothesize the mental rigidity of bvFTD prevents
shifting viewpoints and fixate on just one. Relatedly,
bvFTD patients may exhibit compulsive perseverative
thoughts or behaviors, including collecting, hoarding,
and hyperphagia, while these compulsive changes are
typically absent in fvAD [27].
Recognizing behavioral changes may not be obvious,
as dementia tends to insidiously exaggerate pre-morbid
personality traits. Whereas irritability and depression, as
in Case #2, and emotional lability, as in Case #3, may be
more common in fvAD, constricted affect and apathy
are more typical in bvFTD. The bvFTD “Tin Man” is
more emotionally constrained, whereas the fvAD “Scare-
crow” is often depressed and may be overburdened by
delusions and aggressive behaviors. Each profile creates
a distinct caregiver burden in these disorders [22, 27].
Fig. 4 Chronology of symptoms. The diagram illustrates the severity and timing onset of cognitive impairments, motor manifestations, and
behavioral changes as they may appear across disease stages in fvAD
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One particularly useful clinical scenario to inquire
about is meal time. bvFTD patients eating habits may be
significantly altered, with hyperphagia and food rituals,
and a tendency to seek out and eat one type of food,
such as high-carbohydrate meals, with resultant weight
gain. This contrasts with the weight loss typical of fvAD
patients. Lastly, because of disinhibition and lack of em-
pathy, bvFTD patients have poor table manners, and
may engage in eating off tablemates’ plates or uncouthly
eating with their hands.
Motor manifestations
Motor manifestations may yield valuable insights in dis-
tinguishing bvFTD from fvAD. As cortical myoclonus is
documented in about 50% of patients with fvAD, [28] its
presence favors fvAD over bvFTD. The clinician can im-
agine, for the purpose of mnemonics, the wind jolting
fvAD Scarecrow because of spontaneous and stimulus-
sensitive cortical myoclonus of the hands and face in
contrast with the poorly lubricated bvFTD Tin Man,
which instead renders him parkinsonian.
Parkinsonism is indeed present in 20–30% of patients
with bvFTD. When prominent, mutations in the
microtubule-associated protein tau (MAPT) tend to be
more common than mutations in GRN or C9orf72 genes
[29, 30]. A symmetric tremorless parkinsonism with axial
rigidity and supranuclear gaze palsy has been shown to be
highly predictive of progressive supranuclear palsy path-
ology due to MAPT or, less commonly, C9orf72 muta-
tions. On the other hand, a corticobasal syndrome
(asymmetric parkinsonism with limb dystonia, apraxia,
and cortical sensory loss) is more often due to AD path-
ology than corticobasal degeneration or other disorders
[31]. While parkinsonian features may be present in up to
30% of patients with AD, [32] these appear later in the
disease course [32]. The parkinsonian features of Case #2,
however, were likely contributed to by Lewy body path-
ology, which not uncommonly co-occurs with AD. Finally,
the coexistence of motor neuron disease strongly suggests
pathogenic C9orf72 mutations [29].
Ancillary testing
Structural neuroimaging may also provide clues in the
assessment of these patients. In fvAD there is greater
temporal than frontal atrophy, particularly in the perisyl-
vian area compared to bvFTD [21, 33]. In bvFTD, frontal
regions are more affected, particularly the anterior cin-
gulate, orbitofrontal cortex, middle and superior frontal
gyrus [21, 33].
Cerebrospinal fluid (CSF) biomarkers studies are in-
valuable in distinguishing between fvAD from bvFTD
and healthy controls [25, 34, 35]. Useful CSF biomarkers
include total tau (t-tau), phosphorylated tau (p-tau), and
amyloid β-42 (Aβ42). A higher p-tau/Aβ42 ratio (>0.21)
is observed in fvAD compared to bvFTD (sensitivity and
specificity of about 92%) [25]. In one small series, APOE
ε4 carriers were observed in 52% of patients with fvAD
compared to 19% with bvFTD and 17% controls [21].
Hence, the presence of APOE ε4 allele makes fvAD
more likely than bvFTD.
Treatment
While no randomized clinical trials have been under-
taken in fvAD, acetylcholinesterase inhibitors (donepezil,
rivastigmine, and galantamine) have been shown to be
effective in classic AD but not in bvFTD [36]. In fact,
some bvFTD patients may experience behavioral or cog-
nitive deterioration when exposed to these agents [37].
Likewise memantine, an NMDA receptor antagonist, ap-
proved for moderate to severe AD, has shown no benefit
Table 1 Clinical features distinguishing fvAD from bvFTD
Clinical Features supporting fvAD Clinical Features supporting bvFTD
Memory Early memory complaints Late memory complaints
Language Phonemic and semantic paraphasias Loss of socioemotional aspects of speech
Fluency Semantic > phonemic fluency impairment Phonemic > semantic fluency impairment
Behavioral Compulsive or perseverative behaviors
are uncommon
Collection or hoarding, and ritualistic and disinhibited
behaviors (particularly involving food)
Personality Change Agitation and irritability Early apathy, disinhibition, loss of empathy
Thought Content Delusions (theft, infidelity, and paranoid) Mental rigidity
Body Habitus Weight loss associated with depression Weight gain associated with hyperphagia
Movement Disorder Myoclonus (often mischaracterized as tremor),
late parkinsonism
Early parkinsonism
Brain MRI pattern Symmetric atrophy (temporal > frontal, posterior
corpus callosum, and perisylvian)
Symmetric (~MAPT mutations) or asymmetric
(~GRN mutations) frontotemporal atrophy
CSF findings CSF p-Tau/Aβ42 ratio (>0.21 ng/mL) CSF progranulin levels (<60 ng/mL)- not validated in
clinical practice
Biomarkers APOE ε4 allele positive No relation to APOE allele
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in patients with bvFTD [38]. Thus, the different pharma-
cologic response to treatment in AD versus bvFTD high-
lights the need to clinically distinguish these disorders.
Future clinical trials will require greater sophistication in
patient selection not only for symptomatic but also
disease-modifying interventions, and will assist efforts in
developing reliable serologic and imaging biomarkers of
disease trait and progression for each form of frontal
dementia.
Conclusion
Our cases highlight several features, which in hindsight
should have supported a diagnostic revision to fvAD from
bvFTD: early memory involvement, impaired semantic
fluency, paraphasic errors and myoclonus (Table 1). Dis-
tinguishing between fvAD and bvFTD may be challenging
for the clinician, as evidenced by our three cases whom
were initially diagnosed with bvFTD but were found to
have primarily AD pathology. Improving the clinical diag-
nosis of bvFTD and fvAD is important to optimize patient
care, improve disease-specific counseling to patients and
caregivers, and assist with selective patient recruitment for
future studies of disease-modifying interventions. While
disease-specific biomarkers remain elusive, larger case
series may further refine the Wizard of Oz analogy to help
in the clinical distinction between fvAD and bvFTD.
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